Inclusion Criteria:

          -  Histologically confirmed Grade 1, 2, or 3a FL or nodal MZL, splenic MZL, or extra
             nodal MZL

          -  Willingness to avoid pregnancy or fathering children

          -  In the opinion of the investigator, be able and willing to receive adequate mandatory
             prophylaxis and/or therapy for thromboembolic events (eg, aspirin 70-325 mg daily or
             low-molecular-weight heparin)

          -  Previously treated with at least 1 prior systemic anti-CD20 immunotherapy or
             chemo-immunotherapy

          -  Documented relapsed, refractory, or PD after treatment with systemic therapy

          -  ECOG performance status of 0 to 2

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding.

          -  Any histology other than FL and MZL or clinical evidence of transformed lymphoma

          -  Prior non-hematologic malignancy

          -  Congestive heart failure

          -  HCV positivity, chronic HBV infection or history of HIV infection

          -  Active systemic infection

          -  CNS lymphoma involvement

          -  Any systemic anti-lymphoma and/or investigational therapy within 28 days prior to the
             start of Cycle 1

          -  Prior use of lenalidomide in combination with rituximab